Genmab A/S Sponsored ADR $GMAB Shares Sold by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC lessened its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 7.7% during the second quarter, HoldingsChannel reports. The firm owned 20,419 shares of the company’s stock after selling 1,704 shares during the period. Sequoia Financial Advisors LLC’s holdings in Genmab A/S were worth $422,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Orbis Allan Gray Ltd lifted its stake in shares of Genmab A/S by 102.8% in the first quarter. Orbis Allan Gray Ltd now owns 5,710,741 shares of the company’s stock worth $111,816,000 after acquiring an additional 2,895,179 shares in the last quarter. Brandywine Global Investment Management LLC lifted its stake in shares of Genmab A/S by 6.0% in the first quarter. Brandywine Global Investment Management LLC now owns 1,717,397 shares of the company’s stock worth $33,627,000 after acquiring an additional 97,633 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in shares of Genmab A/S by 112.4% in the first quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company’s stock worth $24,634,000 after acquiring an additional 665,893 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Genmab A/S by 111.5% in the first quarter. Russell Investments Group Ltd. now owns 1,080,129 shares of the company’s stock worth $21,149,000 after acquiring an additional 569,345 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its stake in shares of Genmab A/S by 1.7% in the first quarter. Envestnet Asset Management Inc. now owns 736,326 shares of the company’s stock worth $14,417,000 after acquiring an additional 12,545 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Wall Street Zen cut Genmab A/S from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Truist Financial boosted their price target on Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, July 8th. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target on the stock in a research note on Tuesday, September 23rd. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Genmab A/S in a research note on Wednesday, October 15th. Finally, Zacks Research raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Genmab A/S currently has an average rating of “Moderate Buy” and an average target price of $40.80.

Genmab A/S Stock Down 7.9%

Shares of Genmab A/S stock opened at $30.54 on Tuesday. The firm has a market cap of $19.61 billion, a P/E ratio of 15.35, a P/E/G ratio of 1.85 and a beta of 0.98. Genmab A/S Sponsored ADR has a fifty-two week low of $17.24 and a fifty-two week high of $33.65. The business has a 50-day moving average price of $28.14 and a 200 day moving average price of $23.47.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.15. The firm had revenue of $925.00 million during the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.